CytomX Therapeutics (CTMX) PT Raised to $2.50 at Jefferies, 'EGFRxCD3 on Track for Ph1a Data in 2H24'
Tweet Send to a Friend
(Updated - March 12, 2024 12:04 PM EDT)
Jefferies analyst Roger Song raised the price target on CytomX Therapeutics ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Jefferies analyst Roger Song raised the price target on CytomX Therapeutics ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
